依美昔单抗 （INN ：ecromeximab；开发代号：KW2871 ）是一种嵌合单克隆抗体 ，正在开发用于治疗恶性黑色素瘤 。[1] [2] 转移性黑色素瘤 进行I期临床试验，[3] 干扰素α2b 联合进行了II期临床试验。[4] [5]
该药物由协和发酵工业株式会社开发。截至2015年12月，开发已停止。[6]
参考资料 [ 编辑 ]
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab , American Medical Association .^ Clinical trial number NCT00679289
^ Forero, Andres; Shah, Jatin; Carlisle, Ronda; Triozzi, Pierre L.; LoBuglio, Albert F.; Wang, Wen-Quan; Fujimori, Matt; Conry, Robert M. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma . Cancer Biotherapy & Radiopharmaceuticals. 2006-12, 21 (6). ISSN 1084-9785 PMID 17257071 doi:10.1089/cbr.2006.21.561 ^ Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma - Full Text View - ClinicalTrials.gov . clinicaltrials.gov. [2024-03-06 ] （英语） . ^ Tarhini, Ahmad A.; Moschos, Stergios J.; Lin, Yan; Lin, Hui-Min; Sander, Cindy; Yin, Yan; Venhaus, Ralph; Gajewski, Thomas F.; Kirkwood, John M. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma . Melanoma Research. 2017-08, 27 (4). ISSN 1473-5636 PMID 28489678 doi:10.1097/CMR.0000000000000353 ^ Adis insight: Ecromeximab
